Characterisation of a cellular model of cardiomyopathy, in the rabbit, produced by chronic administration of the anthracycline, epirubicin

Journal of Molecular and Cellular Cardiology

Volumn 29, Issue 12, 1997, Pages 3385-3397

  Kelso, Elizabeth J ^a   Geraghty, Robert F ^a   McDermott, Barbara J ^a   Cameron, C H S ^a   Nicholls, D Paul ^b   Silke, Bernard ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b ROYAL VICTORIA HOSPITAL   (United Kingdom)

Author keywords

Anthracycline; Cardiomyocyte; Cardiomyopathy; Epirubicin; Heart failure; adrenoceptor

Indexed keywords

ANTHRACYCLINE; CALCIUM ION; COLLAGENASE; EPIRUBICIN; ISOPRENALINE;

ACTION POTENTIAL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CALCIUM CURRENT; CARDIOMYOPATHY; CONTROLLED STUDY; ELECTROSTIMULATION; HEART ELECTROPHYSIOLOGY; HEART MUSCLE CONTRACTILITY; HEART MUSCLE INJURY; INOTROPISM; MALE; MUSCLE FIBRIL; NONHUMAN; PRIORITY JOURNAL; RABBIT; SARCOPLASMIC RETICULUM;

ANIMALIA; ORYCTOLAGUS CUNICULUS;

EID: 0031444833     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1006/jmcc.1997.0563     Document Type: Article

References (49)

1. ARENA E, BIONDO R, D'ALESSANDRO N, DUSONCHET L, GEBBIA N, GERBASI F, 1974. DNA, RNA and protein synthesis in heart liver and brain of mice treated with daunorubicin or adriamycin. Int Res Commun Sys Med Sci 2: 1053-1061.
2. ARNOLDA L, MCGRATH B, COCKS M, SUMITHRAN E, JOHNSTON C, 1985. Adriamycin cardiomyopathy in the rabbit: an animal model of low output cardiac failure with activation of vasoconstrictor mechanisms. Cardiovasc Res 19: 378-382.
3. ASAYAMA J, YAMAHARA Y, TATSUMI T, MIYAZAKI H, INOUE M, OMORI I, INOUE D, NAKAGAWA M, 1992. Acute effects of doxorubicin on skinned fibres of guinea-pigs. Cardiovasc Res 26: 371-375.
4. AZUMA J, SPERELAKIS N, HASEGAWA H, TANIMOTO T, VOGEL S, OGURA K, AWATA N, SAWAMURA A, HARADA H, ISHIYAMA T, MORITA Y, YAMAMURA Y, 1981. Adriamycin cardiotoxicity: possible pathogenic mechanisms. J Mol Cell Cardiol 13: 781-397.
5. BILLINGHAM ME, MASON JW, BRISTOW MR, DANIELS JR, 1978. Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep 62: 865-872.
6. BOUCEK RJ, OLSON RD, BRENNER DE, OGUNBUNMI EM, FLEISCHER S, 1987. The major metabolite of doxorubicin is a potent inhibition of membrane associated ion pumps. J Biol Chem 262: 15851-15856.
7. BRISTOW MR, 1982. Toxic cardiomyopathy due doxorubicin. Hosp Pract 17: 101-111.
8. BRISTOW MR, MINOBE WA, BILLINGHAM ME, MARMOR JB, JOHNSON GA, ISHIMOTO BM, SAGEMAN WS, 1981. Anthracycline-associated cardiac and renal damages in rabbits. Evidence for mediation by vasoactive substances. Lab Invest 45: 157-168.
9. CALDERONE A, DE CHAMPLAIN J, ROULEAU JL, 1991. Adriamycin-induced changes to the myocardial beta-adrenergic system in the rabbit. J Mol Cell Cardiol 23: 333-342.
10. CAPASSO JM, FITZPATRICK D, ANVERSA P, 1992. Cellular mechanisms of ventricular failure: myocyte kinetics and geometry with age. Am J Physiol 262: H1770-H1781.
11. DODD CA, ATKINSON JB, OLSON RD, BUCK S, CUSACJ BJ, FLEISCHER S, 1993. Doxorubicin cardiomyopathy is associated with a decrease in calcium release channel of the sarcoplasmic reticulum in a chronic rabbit model. J Clin Invest 91: 1697-1705.
12. DOROSHOW J, 1983. Effect of anthracycline antibiotics on oxygen radical formation in rat heart. Cancer Res 43: 460-472.
13. EARM YE, HO WK, SO I, 1994. Effects of Adriamycin on ionic currents in single cardiac myocytes of the rabbit. J Mol Cell Cardiol 26: 163-172.
14. FELDMAN AM, CATES AE, VEAZEY WB, HERSHBERGERRE, BRISTOW MR, BAUGHMAN KL, BAUMGARTNER WA, VANDOP C, 1988. Increase of the 40,000-mol wt pertussis toxin substrate (G protein) in the failing human heart. J Clin Invest 82: 189-197.
15. FREY M, MANNING D, WILSON J, MOLINOFF P, 1989. Alterations in the catalyst adenylate cyclase and the inhibitory guanine nucleotide regulatory protein in experimental heart failure. JACC 13: 179.
16. FRIEDMAN MA, BOZDECH MJ, BILLINGHAM ME, RIDER AK, 1978. Doxorubicin cardiotoxicity: serial endomyocardial biopsies and systolic time intervals. JAMA 240: 1603-1606.
17. GOSALVEZ M, VAN ROSSUM GDV, BLANCO MF, 1979. Inhibition of sodium-potassium activated adenosine 5′-triphosphatase and ion-transport by adriamycin. Cancer Res 39: 257-261.
18. GWATHMEY JK, 1991. Morphological changes associated with furazolidine-induced cardiomyopathy: effects of digoxin and propranolol. J Comp Pathol 104: 33-45.
19. JACKSON JA, REEVES JP, MUNTZ KH, 1984. Evaluation of free radical effects and catecholamine alterations in adriamycin cardiotoxicity. Am J Pathol 117: 140-153.
20. JONES SM, KIRBY MS, HARDING SE, VESCOVA G, WANLESS RB, LIBERA LD, POOLE-WILSON PA, 1990. Adriamycin cardiomyopathy in the rabbit: alterations in contractile proteins and myocyte function. Cardiovasc Res 24: 834-842.
21. KELSO EJ, MCDERMOTT BJ, SILKE B, 1995. Actions of the novel vasodilator, flosequinan, in isolated ventricular cardiomyocytes. Br J Pharmacol 25: 376-386.
22. 2+ current in ventricular cardiomyocytes. Eur J Pharmacol 308: 351-355.
23. KELSO EJ, GERAGHTY RF, MCDERMOTT BJ, TRIMBLE ER, NICHOLLS DP, SILKE B, 1996b. Mechanical effects of ET-1 in cardiomyocytes isolated from normal and heart-failed rabbits. Mol Cell Biochem 157: 149-155.
24. KIM DH, LANDRY AB, LEE YS, KATZ AM, 1989. Doxorubicin-induced calcium release from cardiac sarcoplasmic reticulum vesicles. J Mol Cell Cardiol 21: 433-436.
25. LAUNCHBURY AP, 1992. Doxorubicin: Epirubicin dosage ratios. Technical information booklet. Farmatalia Carlo Erba Ltd.
26. LONGABAUGH J, VATNER D, VATNER S, HOMCY C, 1988. Decreased stimulatory guanosine triphosphate binding protein in dogs with pressure-overload left ventricular failure. J Clin Invest 81: 420-424.
27. MOURIDSEN HT, ALFTHAN C, BASTHOLT L, BERGH J, DALMARK M, EKSBORG S, HELLSTEN S, KJAER M, PETERSON C, SKOVSGARD T, SORENSEN JB, TROPE C, AAOBO K, 1990. Current Status of epirubicin (Farmorubicin) in the treatment of solid tumors. Acta Oncologica 29: 257-347.
28. OLSON HM, CAPEN CC, 1977. Subacute cardiotoxity of adriamycin in the rat; biochemical and ultrastructural investigations. Lab Invest 37: 386-394.
29. ONDRIAS K, BORGATTA L, KIM DH, EHRLICH BE, 1990. Effects of doxorubicin on the calcium release channel from sarcoplasmic reticulmn of cardiac muscle. Circ Res 67: 1167-1174.
30. PACKER M, 1992. Pathophysiology of chronic heart failure. Lancet I: 88-95.
31. 2+ release from isolated sarcoplasmic reticulum. J Biol Chem 264: 6142-6148.
32. 2+ release channel from rat cardiac sarcoplasmic reticulum: possible receptor-mediated mechanism of doxorubicin cardiomyopathy. Mol Pharmacol 37: 503-514.
33. PIPER HM, MILLAR BC, MCDERMOTT BJ, 1989. The negative inotropic effect of neuropeptide y on the ventricular cardiomyocyte. Naunyn Schmied Arch Pharmacol 340: 333-337.
34. PRITSOS CA, SOKOLOFF M, GUSTAFSON DL, 1992. PZ-51 (Ebselen) in vivo protection against adriamycin-induced mouse cardiac and hepatic lipid peroxidation and toxicity. Biochem Pharmacol 44: 839-841.
35. RHODEN W, HASLETON P, BROOKS N, 1993. Anthracyclines and the heart. Br Heart J 70: 499-502.
36. ROBISON TW, GIRI SN, 1986. Effects of chronic administration of doxorubicin on myocardial beta-adrenergic receptors. Life Sci 39: 731-736.
37. SEN L, O'NEILL M, MARSH JD, SMITH TW, 1990. Myocyte structure, function and calcium kinetics in the cardiomyopathic hamster heart. Am J Physiol 259: H1533-H1543.
38. SHENASA H, CALDERONE A, VERMEULEN M, PARADIS P, STEPHENS H, CARDINAL R, CHAMPLAIN J, ROULEAU JL, 1990. Chronic doxorubicin induced cardiomyopathy in rabbits: mechanical, intracellular action potential, and β-adrenergic characteristics of the failing myocardium. Cardiovasc Res 24: 591-604.
39. SINGAL PK, PANAGIA V, 1984. Direct effects of adriamycin on the rat heart sarcolemma. Res Commun Chem Pathol Pharmacol 43: 67-77.
40. 2+ binding and lipid peroxidation but depresses myocardial function. Am J Physiol 250: H419-425.
41. SINGAL PK, SEGSTRO RJ, SINGH RP, KUTRYK MJ, 1985. Changes in lysosomal morphology and enzyme activities during the development of adriamycin-induced cardiomyopathy. Can J Cardiol 1: 139-147.
42. SINGAL PK, DEALLY CMR, WEINBERG LE, 1987. Subcellular effects of adriamycin in the heart: a concise review. J Mol Cell Cardiol 19: 817-828.
43. SINGAL PK, SIVESKI-ILISKOVIC N, HILL M, THOMAS TP, LI T, 1995. Combination therapy with probucol prevents adriamycin-induced cardiomyopathy. J Mol Cell Cardiol 27: 1055-1063.
44. SlVESKI-lLISKOVIC N, THOMAS TP, KAUL N, SLEZAK J, SlNGAL PK, 1994. Doxorubicin-induced cardiomyopathy: a model of congestive heart failure. In: Nagano M, Takeda N, Dhalla NS (eds). The Cardiomyopathic Heart. NY: Raven Press Ltd., 277-283.
45. SPINALE FG, FULBRIGHT BM, MUKHERJEE R, TANAKA R, Hu J, CRAWFORD FA, ZILE MR, 1992. Relation between ventricular and myocyte function with tachycardia-induced cardiomyopathy. Circ Res 71: 174-187.
46. TONG J, GANGULY PK, SINGAL PK, 1991. Myocardial adrenergic changes at two stages of heart failure due to adriamycin treatment in rats. Am J Physiol 260: H909-H916.
47. TORTI FM, BRISTOW MM, LUM BL, CARTER SK, HOWES AE, ASTON DA, BROWN BW, HANNIGAN JF, MEYERS FJ, MITCHELL EP, BILLINGHAM ME, 1986. Cardiotoxicity of epirubicin and doxorubicin: assessment by endomyocardial biopsy. Cancer Res 46: 3722-3727.
48. VATNER D, VATNER S, FUJU A, HOMCY C, 1984. Loss of high affinity cardiac beta-adrenergic receptors in dogs with heart failure. J Clin Invest 73: 2259-2264.
49. WANLESS RB, ANAND IS, POOLE-WILSON PA, HARRIS P, 1987. An experimental model of chronic cardiac failure using adriamycing in the rabbit: central haemodynamics and regional blood flow. Cardiovasc Res 21: 7-13.